Skip to main content

Table 2 Postoperative complications and mortality

From: Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease

  Patients with COPD (n = 130)
LAMA/LABA LAMA p value* No-BD p value**
n = 64 n = 23 n = 43
Complications      
 Any 14 (21.9) 12 (52.2) 0.007 16 (37.2) 0.083
 Pneumonia 7 (10.9) 6 (26.1) 0.081 7 (16.3) 0.422
 Acute respiratory failure 1 (1.6) 2 (8.7) 0.124 2 (4.7) 0.342
 Prolonged air leakage 6 (9.4) 5 (21.7) 0.126 11 (25.6) 0.012
 Atrial fibrillation 4 (6.3) 2 (8.7) 0.776 4 (9.3) 0.557
 Introduction of HOT 3 (4.7) 3 (13.0) 0.008 0 0.176
30-day mortality 0 0 0
90-day mortality 0 1 (4.3) 0.093 1 (2.3) 0.246
  1. Data are presented as n (%)
  2. COPD chronic obstructive pulmonary disease; LAMA long-acting muscarinic antagonists; LABA long-acting β2-agonists; BD bronchodilator; HOT home oxygen therapy
  3. *Significance of LAMA/LABA versus LAMA
  4. **Significance of LAMA/LABA versus No-BD